Although the exact mechanisms of tumor immune escape through PD-1/PD-L1 interaction are still unclear, tumors with a higher mutational burden, such as melanomas and lung cancers, seem to be more responsive to PD-1/PD-L1 immune checkpoint inhibitors36,37. Here, PDCD1 is linked to neoplasm.